Next Steps in Derm, in partnership with Pigmentary Disorders Exchange Symposium interviewed Dr. Pearl E. Grimes, symposium chair and clinical professor of dermatology at the University of California, Los Angeles. Hear the “why” behind the Pigmentary Disorders Exchange Symposium from its founding chair. Learn what Dr. Grimes believes is a common myth about pigmentary disorders. Plus hear what makes the symposium a unique offering in dermatology.
Further Reading
If you want to read about the dermatologic conditions addressed at the Pigmentary Disorders Exchange Symposium, check out the following articles published in the Journal of Drugs in Dermatology:
Optimizing Melasma Management With Topical Tranexamic Acid: An Expert Consensus
ABSTRACT
Because of its complex pathogenesis, chronicity, and high rates of recurrence, melasma is regarded as a challenging skin disorder. Topical treatments are often offered as first-line therapy. However, many patients are unaware that melasma is recurrent and requires long-term management. Hydroquinone is effective for controlling relapses and has become the standard of care for melasma in many countries. Nonetheless, it is limited by its side effect profile. Certain patient profiles who have had prior therapy and/or are refractory to treatment may be offered an alternative, that is topical tranexamic acid (TXA) alone or in combination with other modalities. This review provides a summary of current evidence on topical TXA as a treatment for certain case profiles. This paper aims to fill knowledge gaps in terms of currently available options, highlighting the role of topical TXA alone or in combination with other active ingredients (ie, topical TXA 2% with patented delivery technology).
Getting to the Core of Contemporary Therapies for Post-Inflammatory Hyperpigmentation
ABSTRACT
Post-inflammatory hyperpigmentation (PIH) is a typical complication of inflammatory dermatoses that more frequently and severely affects people with darker skin. External insults to the skin, such as burn injuries, dermatologic treatments, and intrinsic skin disorders (eg, eczema and acne), are common causes of PIH. Individuals with darker skin are prone to develop PIH, which can cause substantial psychological suffering. PIH can be prevented or alleviated. When this happens, it is essential to point out what is causing it and treat it as soon as possible to prevent inflammation and PIH from progressing. If the inflammatory symptoms go away or there is no evidence of inflammation at the time of diagnosis, PIH treatments should be evaluated. To hasten the resolution of PIH, treatment should begin as soon as possible. Treatment begins with the care of the initial inflammatory condition. Topical medications, chemical peels, laser and light-based treatment, phototherapy, and other therapeutic modalities are offered to treat PIH. Understanding the therapy options available helps the physician in choosing the best treatment for each patient. With these backgrounds, the current review aimed to discuss the epidemiology, pathogenesis, clinical presentation, and available treatment options for the PIH.
Did you enjoy this video interview? Find more here.
